報價延遲最少15分鐘:2025/06/01 13:07 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.638 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.64/-0.56
|
|
企業價值
49.53M
|
| 資產負債 |
|
每股賬面淨值
0.09
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
9.29M
|
|
每股收益
0.05
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 13:07 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others. |